Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Jan;9(1):46-53.
doi: 10.2215/CJN.04700513. Epub 2013 Oct 31.

C3 glomerulopathy: clinicopathologic features and predictors of outcome

Affiliations
Comparative Study

C3 glomerulopathy: clinicopathologic features and predictors of outcome

Nicholas R Medjeral-Thomas et al. Clin J Am Soc Nephrol. 2014 Jan.

Abstract

Background and objectives: The term C3 glomerulopathy describes renal disorders characterized by the presence of glomerular deposits composed of C3 in the absence of significant amounts of Ig. On the basis of electron microscopy appearance, subsets of C3 glomerulopathy include dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The full spectrum of histologic change observed in C3 glomerulopathy has yet to be defined and pathologic predictors of renal outcome within this patient population remain largely unknown. This study thus characterized a large C3 glomerulopathy cohort and identified clinicopathologic predictors of renal outcome.

Design, setting, participants, & measurements: All patients with kidney biopsies fulfilling criteria for C3 glomerulopathy from two quaternary renal centers within the United Kingdom and Ireland between 1992 and 2012 were retrospectively reviewed. We recorded histologic, demographic, and clinical data and determined predictors of ESRD using the Cox proportional hazards model.

Results: Eighty patients with C3 glomerulopathy were identified: 21 with DDD and 59 with C3GN. Patients with DDD were younger, more likely to have low serum C3 levels, and more likely to have crescentic GN than patients with C3GN. Patients with C3GN were older and had more severe arteriolar sclerosis, glomerular sclerosis, and interstitial scarring than patients with DDD. Of 70 patients with available follow-up data, 20 (29%) progressed to ESRD after a median of 28 months. Age >16 years, DDD subtype, and crescentic GN were independent predictors of ESRD within the entire cohort. Renal impairment at presentation predicted ESRD only among patients with DDD.

Conclusions: Although detailed serologic and genetic data are lacking, this study nevertheless identifies important clinicopathologic distinctions between patients with DDD and C3GN. These include independent predictors of renal outcome. If replicated in other cohorts, these predictors could be used to stratify patients, enabling application of emerging mechanism-based therapies to patients at high risk for poor renal outcome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Electron micrographs showing a range of appearances that may be seen in C3 glomerulopathy. (A) A case of dense deposit disease showing the pathognomonic densely osmiophilic transformation of the glomerular basement membrane. (B) A case of C3GN showing poorly circumscribed electron dense material expanding the mesangium and some small deposits of similar material within the capillary basement membrane. (C) A case of C3GN showing expansion of the mesangium by electron dense material and irregular thickening of the glomerular capillary basement membrane by intramembranous and subepithelial electron dense deposits. (D) A case of C3GN showing scattered, relatively discrete, electron dense deposits in the mesangium and within the capillary wall basement membrane.
Figure 2.
Figure 2.
Kaplan–Meier analysis of renal survival by C3 glomerulopathy subtype. The analysis demonstrates no significant difference in ESRD free renal survival between dense deposit disease (DDD) and non-DDD (C3GN) C3 glomerulopathy subtypes.

References

    1. Walport MJ: Complement. First of two parts. N Engl J Med 344: 1058–1066, 2001 - PubMed
    1. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P: The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol 41: 355–367, 2004 - PubMed
    1. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA: Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419–421, 2005 - PubMed
    1. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF: Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 16: 1392–1403, 2005 - PubMed
    1. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC: C3 glomerulopathy: A new classification. Nat Rev Nephrol 6: 494–499, 2010 - PubMed

Publication types

MeSH terms